Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan sucrosofate - Ipsen

Drug Profile

Irinotecan sucrosofate - Ipsen

Alternative Names: BAX-2398; Irinotecan liposome injection - Merrimack; Liposomal irinotecan - Ipsen/Servier; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02; S-095013; SHP-673

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academic Medical Center; HERMES BioSciences
  • Developer Academic Medical Center; AIO Studien gGmbH; Bristol-Myers Squibb; Emory University; Federation Francophone de Cancerologie Digestive; Ipsen; Medica Scientia Innovation Research; Merrimack Pharmaceuticals; National Cancer Institute (USA); PharmaEngine; Rhode Island Hospital; Servier; Shire; Taiho Pharmaceutical; University of California at San Francisco; University of Florida; University of Michigan
  • Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase III Small cell lung cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Gastrointestinal cancer; Glioblastoma
  • Phase I Solid tumours
  • No development reported Glioma

Most Recent Events

  • 13 Feb 2024 Registered for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV)
  • 30 Jan 2024 Servier plans a phase II trial in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) (IV, Infusion) (NCT06225999)
  • 18 Jan 2024 Efficacy data from the phase-III NAPOLI-3 trial in Pancreatic cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024),
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top